Ann Pediatr Endocrinol Metab.  2013 Dec;18(4):173-178. 10.6065/apem.2013.18.4.173.

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty

• Kim YJ
• Lee HS
• Lee YJ
• Lim JS
• Kim SY
• Kim EY
• Jin DK
• Hwang IT
• Hwang JS

• KMID: 2266351
• DOI: http://doi.org/10.6065/apem.2013.18.4.173

Abstract

PURPOSE
We evaluated the efficacy, safety and psychological aspect of monthly administrations of the gonadotropin-releasing hormone agonists (GnRHa), leuprolide acetate depot (Luphere depot 3.75 mg), in patients with precocious puberty.
METHODS
A total of 54 girls with central precocious puberty were administered with leuprolide acetate (Luphere depot 3.75 mg) every four weeks over 24 weeks. We evaluated the percentage of children exhibiting a suppressed luteinizing hormone (LH) response to GnRH (LH peak< or =3 IU/L), peak LH/follicle stimulating hormone (FSH) ratio of GnRH stimulation test less than 1, change in bone age/chronologic age ratio, change in the Tanner stage and change in eating habit and psychological aspect.
RESULTS
(1) The percentage of children exhibiting a suppressed LH response to GnRH, defined as an LH peak< or =3 IU/L at 24 weeks was 96.3 % (52/54). (2) The percentage of children exhibiting peak LH/FSH ratio<1 at 24 weeks of the study was 94.4 % (51/54). (3) The ratio of bone age and chronological age significantly declined from 1.27+/-0.07 to 1.24+/-0.01 after the 6 months of the study. (4) The mean Tanner stage manifested a significant change 2.3+/-0.48 at baseline, down to 1.70+/-0.61 at 24 weeks. (5) Based on the questionnaires, the score for eating habits showed a significant change from the baseline 34.0+/-6.8 to 31.3+/-6.8. (6) The psychological assessment did not exhibit a significant difference except with scores for sociability, problem behavior total score and other problems.
CONCLUSION
The leuprolide 3.75 mg (Luphere depot) is useful and safety for treating children with central precocious puberty.

Keyword

Leuprolide acetate; Central precocious puberty; Treatment outcome

MeSH Terms

Child
Eating
Female*
Gonadotropin-Releasing Hormone
Humans
Leuprolide*
Luteinizing Hormone
Puberty, Precocious*
Treatment Outcome
Surveys and Questionnaires
Gonadotropin-Releasing Hormone
Leuprolide
Luteinizing Hormone

Figure

• 

  Fig. 1 Patient disposition. FAS, full analysis set; PPS, per-protocol set.

Reference

1. Fahmy JL, Kaminsky CK, Kaufman F, Nelson MD Jr, Parisi MT. The radiological approach to precocious puberty. Br J Radiol. 2000; 73:560–567. PMID: 10884758.

2. Dixon JR, Ahmed SF. Precocious puberty. Pediatr Child Health. 2007; 17:343–348.

3. Brauner R. Central precocious puberty in girls: prediction of the aetiology. J Pediatr Endocrinol Metab. 2005; 18:845–847. PMID: 16279360.

4. Larsen PR, Kronenberg HM, Melmed S, Polansky KS. Puberty: ontogenety, neuroendocrinology, physiology and disorder. In : Larsen PR, Kronenberg HM, Melmed S, Polansky KS, editors. Williams textbook of endocrinology, physiology. 10th ed. Philadelphia: Saunders;2003. p. 1115–1239.

5. Parker KL, Lee PA. Depot leuprolide acetate for treatment of precocious puberty. J Clin Endocrinol Metab. 1989; 69:689–691. PMID: 2503536.

6. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr. 1992; 121:634–640. PMID: 1403402.

7. Bonat S, Pathomvanich A, Keil MF, Field AE, Yanovski JA. Self-assessment of pubertal stage in overweight children. Pediatrics. 2002; 110:743–747. PMID: 12359788.

8. Greulich WW, Pyle SI. Radiologic atlas of skeletal development of the hand and wrist. 2nd edition. Stanford: Stanford University Press;1959.

9. Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr. 1994; 83:1052–1056. PMID: 7841703.

10. Larsen PR, Kronenberg HM, Melmed S, Polansky KS. Korean version of child behavior check list (K-CBCL). Seoul: ChungAng Aptitude Publishing Co.;1997.

11. Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun. 1974; 60:406–413. PMID: 4608231.

12. Faure N, Labrie F, Lemay A, Belanger A, Gourdeau Y, Laroche B, et al. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil Steril. 1982; 37:416–424. PMID: 6800852.

13. Freitas S, Merkle HP, Gander B. Ultrasonic atomisation into reduced pressure atmosphere: envisaging aseptic spray-drying for microencapsulation. J Control Release. 2004; 95:185–195. PMID: 14980767.

14. Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol. 2010; 398639. PMID: 21437000.

15. Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, et al. French Leuprorelin Trial Group. Treatment of central precocious puberty with depot leuprorelin. Eur J Endocrinol. 1995; 132:699–704. PMID: 7788009.

16. Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011; 2011:7. PMID: 21860633.

17. McNicholas F, Dooley B, McNamara N, Lennon R. The impact of self-reported pubertal status and pubertal timing on disordered eating in Irish adolescents. Eur Eat Disord Rev. 2012; 20:355–362. PMID: 22488753.

18. Zheng F, Zhu H, Jiang YJ. Psychological behavior of girls with idiopathic central precocious puberty before and after treatment with gonadotropin-releasing hormone analogue. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008; 37:289–294. PMID: 18546533.

19. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010; 95:109–117. PMID: 19897682.